A Study of 99mTc-3PRGD2 Injection in Lung Cancer Patient
|
|
文献详情
编号/登记号：
注册时间：
研究开始时间：
研究结束时间：
项目类型：
本院角色：
多中心研究：
招募状态：
试验分期：
研究疾病/适应症：
研究类型：
研究单位：[1]RDO Pharm.[2]Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050000河北医科大学第四医院[3]Sino-Japanese Friendship Hospital of Jilin Universit Changchun, Jilin, China, 130000[4]First Hospital of Shanxi Medical Universit Taiyuan, Shanxi, China, 030000[5]Peking Union Medical College Hospital Beijing, Beijing, China, 100032[6]Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.
The study drug Technetium [99mTc] Hydrazinonicotinamide PEGylated Bicyclic RGD Peptide Injection（99mTc-3PRGD2） of this study is a novel radioactive diagnostic preparation for clinical use as a nuclear medicine molecular probe for tumor SPECT/CT imaging.
After 99mTc-3PRGD2 is injected into the body, it is specifically taken up by integrin receptor-positive tumor tissue, and the image of tumor tissue can be obtained by SPECT/CT, This can be used for molecular imaging diagnosis and individualized treatment of common tumors.
The primary objective of this study was to evaluate the efficacy of 99mTc-3PRGD2 for the diagnosis of lymph node metastasis in lung tumors. The minor objective was to evaluate the efficacy of 99mTc-3PRGD2 in the differential diagnosis of benign and malignant lung tumors and the safety of 99mTc-3PRGD2 in vivo of humans.
